Pfizer’s Lyrica Is First Drug Approved For Fibromyalgia
This article was originally published in The Pink Sheet Daily
Executive Summary
Company has said it believes indication could add $1 billion in incremental Lyrica sales.
You may also be interested in...
Pfizer Discontinues Two Phase III Primary Care Projects
Pfizer is halting development of treatments for generalized anxiety disorder and fibromyalgia.
Pfizer Discontinues Two Phase III Primary Care Projects
Pfizer is halting development of treatments for generalized anxiety disorder and fibromyalgia.
Pfizer's Pain Pipeline No Sore Spot: Firm Pursues Novel Targets, New Markets
Pfizer's investment in pain R&D is aimed at capturing two of the most significant advantages in the pharmaceutical industry: unmet medical need and innovative drug targets. With a track record in the field and over 80 percent of its pain pipeline hitting novel targets, Pfizer should be well-situated to capitalize on that opportunity.